# A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

> **NCT06422507** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 333 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** 8 mg aflibercept (BAY 86-5321) (High Dose)
- **DRUG:** 2 mg aflibercept (EYLEA, BAY 86-5321)
- **OTHER:** Sham

## Key facts

- **NCT ID:** NCT06422507
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-29
- **Primary completion:** 2025-12-29
- **Final completion:** 2026-03-25
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06422507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06422507, "A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06422507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*